Program Description
The introduction of targeted therapies, including small molecule inhibitors targeting BTK and BCL-2, has improved survival outcomes in patients with chronic lymphocytic leukemia (CLL). However, these therapies can also cause class-specific and agent-specific toxicities, impacting adherence. This session will provide a comprehensive overview of CLL and its evolving treatment landscape, focusing on recent updates in treatment guidelines and clinical trial data. Current first- and second-line treatment approaches will be discussed, with an emphasis on treatment selection beyond age and comorbidities with a focus on del(17p)/TP53 mutation status, the continued role of ibrutinib-based regimens, and continuous versus fixed-duration treatment. As oncology pharmacists play a crucial role in collaborating with oncologists to optimize therapy selection, the session will also delve into multidisciplinary strategies to ensure the safety of small molecule inhibitors, including monitoring for and managing cardiac toxicities. Oncology pharmacists will explore strategies for managing BTK inhibitor intolerance and resistance, best practices for toxicity management, and treatment options for patients refractory to first-line therapies, emphasizing opportunities for shared decision-making.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: August 19, 2025
Expiration date: August 19, 2026
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Manage frontline treatment plans for patients with chronic lymphocytic leukemia (CLL) by incorporating patient- and disease-specific considerations
- Identify optimized therapeutic sequencing strategies for second-line and subsequent CLL therapies
- Apply effective strategies to monitor and manage toxicities of targeted therapies in CLL